Guideline on Dose-Intensive Chemotherapy for Soft Tissue Sarcoma
Author Information
Author(s): Shailendra Verma, Younus J., Haynes A.E., Stys–Norman D., Blackstein M.
Primary Institution: Cancer Care Ontario’s Program in Evidence-Based Care
Hypothesis
In patients with inoperable locally advanced or metastatic soft tissue sarcoma, does first-line dose-intensive chemotherapy supported by growth factor or autologous bone marrow or stem-cell transplantation improve response rate, time to disease progression, or survival as compared with standard-dose chemotherapy?
Conclusion
Dose-intensive chemotherapy with growth factor support is not recommended for first-line treatment of inoperable locally advanced or metastatic soft tissue sarcoma.
Supporting Evidence
- Dose-intensive chemotherapy with growth factor support is not recommended in the first-line treatment of patients with inoperable locally advanced or metastatic soft tissue sarcoma.
- The data are insufficient to support the use of high-dose chemotherapy with autologous bone marrow or stem-cell transplantation as first-line treatment in this group of patients.
- Eligible patients should be encouraged to enter clinical trials assessing novel approaches or compounds.
Takeaway
This guideline says that using stronger chemotherapy with extra support isn't better for patients with certain types of cancer, and they should consider joining clinical trials instead.
Methodology
A systematic review was conducted, and clinical recommendations were drafted and approved by the Sarcoma Disease Site Group.
Potential Biases
No conflicts of interest were declared by the members of the Sarcoma Disease Site Group.
Limitations
Insufficient data to support the use of high-dose chemotherapy with autologous bone marrow or stem-cell transplantation.
Participant Demographics
Adult patients with inoperable locally advanced or metastatic soft tissue sarcoma.
Want to read the original?
Access the complete publication on the publisher's website